INSERM, UMR 1229, RMeS, Regenerative Medicine and Skeleton, Université de Nantes, ONIRIS, Nantes F-44042, France; CHU Nantes, Pharmacie Centrale, PHU 11, Nantes F-44093, France; Université de Nantes, UFR Sciences Biologiques et Pharmaceutiques, Nantes F-44035, France; Université de Nantes, UFR Odontologie, Nantes F-44042, France.
INSERM, UMR 1229, RMeS, Regenerative Medicine and Skeleton, Université de Nantes, ONIRIS, Nantes F-44042, France; Department of Diagnostic Imaging, CRIP, National Veterinary School (ONIRIS), Nantes F-44307, France.
Adv Drug Deliv Rev. 2019 Jun;146:306-324. doi: 10.1016/j.addr.2018.04.017. Epub 2018 Apr 26.
Low back pain (LBP), frequently associated with intervertebral disc (IVD) degeneration, is a major public health concern. LBP is currently managed by pharmacological treatments and, if unsuccessful, by invasive surgical procedures, which do not counteract the degenerative process. Considering that IVD cell depletion is critical in the degenerative process, the supplementation of IVD with reparative cells, associated or not with biomaterials, has been contemplated. Recently, the discovery of reparative stem/progenitor cells in the IVD has led to increased interest in the potential of endogenous repair strategies. Recruitment of these cells by specific signals might constitute an alternative strategy to cell transplantation. Here, we review the status of cell-based therapies for treating IVD degeneration and emphasize the current concept of endogenous repair as well as future perspectives. This review also highlights the challenges of the mobilization/differentiation of reparative progenitor cells through the delivery of biologics factors to stimulate IVD regeneration.
下腰痛(LBP)常与椎间盘(IVD)退变相关,是一个主要的公共健康问题。目前,LBP 通过药物治疗进行管理,如果治疗不成功,则采用侵入性手术,但这些方法并不能阻止退行性过程。鉴于 IVD 细胞耗竭在退行性过程中至关重要,因此人们考虑用修复细胞补充 IVD,这些细胞可以与生物材料一起或不与生物材料一起使用。最近,在 IVD 中发现了修复性干细胞/祖细胞,这增加了对内源性修复策略的兴趣。通过特定信号招募这些细胞可能是细胞移植的替代策略。在这里,我们回顾了用于治疗 IVD 退变的基于细胞的治疗方法的现状,并强调了内源性修复的当前概念以及未来的展望。本综述还强调了通过输送生物制品因子来动员/分化修复祖细胞以刺激 IVD 再生所面临的挑战。